Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…
TRENDS
With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
By Reiji Anasako As the Japanese SGLT2 inhibitor market starts to get on a growth track, competition in the crowded space is expected to heat up particularly among the top three products. First-in-class Suglat (ipragliflozin) is now closely trailed by…
To read the full story
TRENDS
- Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
November 28, 2018
- Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
November 15, 2018
- Hep C Market Shrinking towards Disease Elimination in 2030
October 12, 2018
- “Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
September 4, 2018
- Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
August 8, 2018
While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…
Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…
To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…